October 01, 2013
A New Jersey federal judge on Tuesday approved a $688 million settlement to settle claims that Merck & Co. Inc. and its subsidiary Schering-Plough Corp. concealed test results on the efficacy of their anti-cholesterol drug Vytorin, while also awarding $140 million in attorneys' fees.
August 29, 2013
Two special masters recommended Wednesday that a New Jersey federal court approve $140 million in attorneys' fees sought by class counsel who settled for $688 million two securities class actions alleging Merck & Co. and its Schering-Plough subsidiary hid test results on the efficacy of their anti-cholesterol drug Vytorin.
September 26, 2012
A New Jersey federal judge on Tuesday granted class certification in a pair of related suits brought by investors claiming drugmaker Merck & Co. and subsidiary Schering-Plough hid test results that showed their anti-cholesterol drug Vytorin did not work.